CMIC
Pharmaceutical Value Creator

Overview of Financial Results for FY2023 2nd Quarter/1H

CMIC HOLDINGS Co., Ltd.

May 11, 2023

Copyright ©2020 CMIC Group – All Rights Reserved

Overview of Financial Results

CMIC GROUP CFO

Wataru Mochizuki

CMIC Group Business

Healthcare Solutions

Comprehensive support of medical institutes and medical staff

Support individuals, local governments, etc. with solutions using a new ecosystem of health care

Pharmaceutical Solutions

Comprehensive support for research and development of disease prevention and treatment

Development and manufacturing support for pharmaceutical products and biopharmaceutical API from clinical to commercial

Medical, sales and marketing support for pharmaceuticals, and orphan drugs development to commercialization

CMIC Group Network

27 group companies, 61sites (48 offices, 6 factories, 7 laboratories)
Japan: 14 companies
Overseas: 13 companies



Focus Activities of Mid-term Management Plan (FY2022-25)

Evolution of healthcare business

Comprehensive support for disease prevention, treatment R&D, and marketing

Contribution to sustainable society through services with high social benefits

Progress of 2nd quarter of FY2023

Evolution of healthcare business

harmo:

- Expansion of support for local governments
  - Comprehensive support for measures against COVID-19 infections, ranging from infection prevention to post-infection follow-up
  - New solutions to local government / municipalities

- Strengthening our digital platform with the aim of increasing the individuals' health values
  - Business development centered on "nanacara", a support platform for patients and families
  - New business developed with OKEIOS Inc. utilizing personal data

オケイオス



Progress of 2nd quarter of FY2023

Comprehensive support for disease prevention, treatment R&D, and marketing

- Comprehensive support from drug development, manufacturing, to sales and marketing

  - PVC（Pharmaceutical Value Creator） Model -

  - Consulting for entering the Japanese market and entering the healthcare field from other industries
  - Projects for efficacy and safety evaluation and analysis in cutting-edge areas where modalities are diversifying

- Support combining manufacturing, marketing, and other permits with PVC's value chain

  - Clinical trials in Japan for a treatment for urea cycle disorders

***Urea Cycle Disorders (UCD)**

A congenital deficiency of an enzyme in the urea cycle of the liver results in hyperammonemia, a failure to metabolize ammonia

Progress of 2nd quarter of FY2023

Contribution to sustainable society through services with high social benefits

- Co-sponsorship of the 14th "International Children's Drawing Contest”
  Presentation of the 19th “Society Prize (CMIC Prize) of the AIDS Society of Japan”
  Sponsoring "Rare Disease Day 2023"

- Support for athletes with disabilities

Consolidated income statement (overview)

	FY2022 Q2		FY2023 Q2			
	Amount	Composition ratio	Amount	Composition ratio	Change	Percent Change
	(¥ millions)	(%)	(¥ millions)	(%)	(¥ millions)	(%)
Net sales	51,769	100.0	**59,883**	100.0	+8,114	+15.7
Operating profit	5,743	11.1	**8,546**	14.3	+2,803	+48.8
Ordinary profit	6,169	11.9	**7,665**	12.8	+1,495	+24.2
Profit attributable to owners of parent	3,503	6.8	**6,545**	10.9	+3,042	+86.8
Earnings per share	¥194.07		¥377.14			

The situation in Ukraine had no significant direct impact on the Group during the period under review.

Breakdown of Non-operating income and expenses/Extraordinary income and losses/Income taxes/Profit (loss) attributable to non-controlling interests

(¥ millions)	FY2022 Q2	FY2023 Q2
Non-operating income	530	63
Interest income	1	5
Foreign exchange gains	467	–
Subsidy income	13	26
Other	47	30
Non-operating expenses	104	945
Interest expenses	74	94
Foreign exchange losses	–	809
Share of loss of entities accounted for using equity method	–	19
Other	29	22

(¥ millions)	FY2022 Q2	FY2023 Q2
Extraordinary income	–	3,349
Gain on sale of investment securities	–	3,349
Extraordinary losses	51	86
Loss on retirement of non-current assets	43	27
Loss on valuation of investment securities	8	11
Loss on liquidation of subsidiaries	–	47
Income taxes	2,631	4,388
Profit (loss) attributable to non-controlling interests	(17)	(6)

Sales & Operating profit by reportable segment

		FY2022 Q2 Amount (¥ millions)	**FY2023 Q2** Amount (¥ millions)	Change (¥ millions)	Percent change (%)
Pharmaceutical Solutions	Sales	36,820	**42,309**	+5,488	+14.9
	Operating profit	2,326	**3,559**	+1,233	+53.0
Healthcare Solutions	Sales	15,262	**18,443**	+3,181	+20.8
	Operating profit	4,182	**5,892**	+1,710	+40.9
Adjustments	Sales	(314)	**(870)**	(556)	–
	Operating profit	(765)	**(905)**	(139)	–
Consolidated	Sales	51,769	**59,883**	+8,114	+15.7
	Operating profit	5,743	**8,546**	+2,803	+48.8

*Adjustments

Sales are internal elimination of transactions between reporting segments .

Operating profit represents corporate expenses that are not allocated to each reportable segment and are related to the Company (holding company).

Orders received / Backlog

	FY2022 Q2		FY2023 Q2			
	Orders received (¥ millions)	Backlog (¥ millions)	Orders received (¥ millions)	Percent Change (%)	Backlog (¥ millions)	Percent Change (%)
Pharmaceutical Solutions	44,327	77,688	**40,737**	(8.1)	**76,772**	(1.2)
Healthcare Solutions	15,334	16,947	**19,915**	+29.9	**17,900**	+5.6
Total	59,661	94,636	**60,653**	+1.7	**94,672**	+0.0

Sales composition ratio

FY2022 Q2



Operating profit	¥5,743million
Operating margin	11.1%

FY2023 Q2



Operating profit	¥8,546milllion
Operating margin	14.3%

Sales composition ratio of Pharmaceutical Solutions

FY2022 Q2



Operating profit	¥2,326million
Operating margin	6.3%

FY2023 Q2



Operating profit	¥3,559million
Operating margin	8.4%

Business Segment: CRO Business

Pharmaceutical Solutions

Comprehensive support for research and development of disease prevention and treatment

Business Overview

- Sales increased from the same period of the previous year
- Strengthen comprehensive consulting services for overseas bio ventures entering the Japanese market and other industries entering the healthcare field
- Increase in support for DX (Digital Transformation) promotion and DTx (Digital Therapeutics) entry
- Increase in projects for efficacy and safety evaluation and analysis in cutting-edge areas where modalities are diversifying, such as next-generation antibody drugs, nucleic acid drugs, gene therapeutics, and biomarkers



Focus activities

- Enhanced development support for advanced therapies such as biologics and regenerative medicine
  (full support for filing by Academia and BV)
- Digital applications such as DCT and RWD
- Proactive take on nucleic acid medicine projects via collaboration of laboratories in Japan and the U.S.
- Proactive take on global clinical studies
  (clinical trials in Asia, Japan-US bioanalysis business)
- Business expansion to the U.S. and Asia
- Aim for the #1 share in Japan

Business Segment: CDMO Business

Development and manufacturing support for pharmaceutical products and biopharmaceutical API from clinical to commercial

Business Overview

- Sales increased from the same period of the previous year
- Growing need to ensure stable supply in response to the spread of COVID-19 and generic quality issues
- Increase in manufacturing costs due to higher prices for energy, raw materials, packaging materials, etc.
- Respond to supply shortage risks, such as prolonged delivery times, in cooperation with customers and suppliers
- Delayed recovery in US performance, focus on acquiring new projects



*Business segment profit rate (Negative) 3.9%

Focus activities

- Steady implementation of production at the Ashikaga injectable facility and its contribution to earnings
- Full-scale development of licensing business for formulation technologies (microneedles, etc.)
- Expand business at the new U.S. site
- Strengthen our position as a strategic partner for domestic pharmaceutical companies

Business Segment: Market Solutions Business

Pharmaceutical Solutions

Medical, sales and marketing support for pharmaceuticals, and orphan drugs development to commercialization

Business Overview

- Sales increased from the same period of the previous year
- Received many customer inquiries for MR dispatch services
- Commencement of Phase III clinical trials in Japan for glycerol phenylbutyrate (overseas trade name: Ravicti®), a treatment for urea cycle disorders, and associated increase in R&D expenses



Focus activities

- Expand positioning in the MR dispatch business
- Efficient recruitment of MRs and MSLs
- Provision of hybrid services
- Promotion of multi-channel
- Development of new orphan drugs
- Supporting foreign pharmaceutical companies entering the Japanese market

Sales composition ratio of Healthcare Solutions

FY2022 Q2



Operating profit	¥4,182million
Operating margin	27.4%

FY2023 Q2



Operating profit	¥5,892million
Operating margin	31.9%

Business Segment: Site Support Solutions Business

Comprehensive support of medical institutes and medical staff

Business Overview

- Sales decreased from the same period of the previous fiscal year due to a decline in large new coronavirus vaccine development projects
- Solid orders received
- Expansion of Clinical Trial Office Support for Medical Institutions
- Expand collaboration with academia



Focus activities

- Shifting from treatment to prevention/prognosis market (prophylaxis treatment agents and clinical trials using apps)
- Providing support for university hospital network, etc.
- Providing services in community healthcare

Business Segment: Healthcare Revolution Business

Support individuals, local governments, etc. with solutions using a new ecosystem of health care

Business Overview

- Sales significantly exceeded the same period of the previous year
- Continued support services related to COVID-19
- Expansion of businesses that integrate disease prevention, health information, and IT technologies
  - Increase in the number of medical institutions introducing “nanacara”, a support platform for epilepsy patients and their families, and expansion of target diseases for nanacara-based services
  - Support for local government projects in line with the "Digital Garden Cities and Green Transformation"



Focus activities

- Expansion of healthcare services & utilization of data by using harmo®
- Expansion of healthcare services for local governments and companies
- Expansion of self-screening services
- Nurture and secure healthcare human resources

harmo:

Consolidated balance sheet (assets)



Total assets	+3,935
Cash equivalents	+2,314
Trade receivables	+1,219
Inventory	+898
Other current assets	+821
Non-current assets	(1,317)

Consolidated balance sheet (liabilities and net assets)



Accounts payable	(11)
Other current liabilities	(3,308)
Other non-current liabilities	+18
Interest-bearing debt (excl. lease obligations)	+1,686
Net assets	+5,549

Cash Flows

(¥ millions)	2022/3	2023/3	Increase (decrease)
Cash flows from operating activities	4,011	2,168	(1,842)
Cash flows from investing activities	(3,682)	267	+3,950
Cash flows from financing activities	906	(114)	(1,020)
Effect of exchange rate change on cash and cash equivalents	(278)	(40)	+237
Net increase(decrease) in cash and cash equivalents	956	2,281	+1,325
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	60	–	(60)
Cash and cash equivalents at beginning of period	9,379	11,703	+2,323
Cash and cash equivalents at end of period	10,395	13,984	+3,588

【Key factors】

(Cash flow from operating activities)

・Increase in funds due to recording of profit before income taxes, decrease in funds due to payment of income taxes and bonus payments, etc.

(Cash flow from investing activities)

・Increase in funds from sale of investment securities, decrease in funds from acquisition of fixed assets, etc.

(Cash flow from financing activities)

・Increase in funds due to long-term borrowings, decrease in funds due to cash dividends paid and purchase of treasury shares, etc.

Forecast for FY ending Sep. 2023

Forecast for FY ending Sep. 2023

	2022/9 Actual (¥ millions)	2023/9 Plan (¥ millions)	**2023/9 Forecast (¥ millions)**	Change from the original plan (%)
Net Sales	108,461	95,000	**105,000**	+10.5
Operating profit	11,845	5,000	**10,300**	+106.0
Ordinary profit	13,450	4,700	**9,000**	＋91.5
Profit attributable to owners of parent	8,387	2,900	**7,300**	+151.7
Earnings per share	¥ 469.44	¥ 165.23	**¥ 420.42**	



CMIC CMO becomes an equity-method affiliate and forms a strategic business alliance with Dai Nippon Printing (DNP)

Division Director of CDMO Business
Makoto Matsukawa

Business Alliance with Dai Nippon Printing (DNP)

Reason for Partnership

- ✓ CMIC Group to maintain its strategic policy of developing PVC models and expand and grow CMIC CMO
- ✓ Effective utilization of group resources to create healthcare business and achieve sustainable growth

Details of Cooperation

(1) Development of value-added pharmaceutical products by combining the packaging technology of the DNP Group with the formulation development technology of the CMIC Group

(2) Establishment of an end-to-end system from process development and manufacturing of active pharmaceutical ingredients by the DNP Group to formulation development and manufacturing by the CMIC

(3) Collaboration in the CMIC Group's clinical development and clinical trial site support business, utilizing the DNP Group's technology and know-how

(4) Business Alliance to Build a Healthcare Ecosystem

Joint initiatives with DNP in CDMO business

The joint venture will maintain CMIC CMO's previous management structure and organization, while leveraging DNP's expertise in contract manufacturing in other businesses.

- ✓ CMIC CMO's formulation technology and DNP's packaging technology will be combined to develop value-added formulations that are user-friendly and consider not only production costs but also the environment.
  - Currently developing a product using deoxygenated packaging technology that enables liquid formulation of freeze-dried injectable products that remains stable at room temperature
  - Promoting practical application of drug manufacturing utilizing 3D printing technology (in collaboration with Apricia)

- ✓ Collaboration between DNP's API business unit and CMIC CMO to nurture an integrated business from API to drug product development and manufacturing

- ✓ Application of DNP's production automation system to drug manufacturing

DNP - CMIC API business model



1

Providing one-stop service for pharmaceutical manufacturing

- Provide comprehensive supply chain solutions: from API to formulation
- Design and evaluation of API properties suitable for formulation development and manufacturing
- Packaging design services

2

Competitive API supply

- Procurement of raw materials and intermediates from reliable channels at low prices
- Stable supply of domestic brand high quality API
- Efficient and highly productive operation utilizing compact sites/facilities

DNP alliance model to develop & manufacture GE new products

In the development of new GE products, we have concluded joint development and manufacturing consignment agreements with multiple GE manufacturers, and have CMIC/DNP handle everything from API to development and manufacturing, with the aim of improving operational efficiency and reducing costs through formation of an ecosystem (platform)



***As an alternative, consider OEM models for GE products using CMIC Group's manufacturing and marketing capabilities**

CMIC CMO Organization (from June 2023)

1	Name	CMIC CMO Co., Ltd
2	Address	1-1-1 Shibaura, Minato-ku, Tokyo
3	Title and name of representative	Toshiki Sugimoto, Chairman and Representative Director (DNP) Makoto Matsukawa, CEO and Representative Director
4	Business	Manufacture, import, export and sales of pharmaceutical products
5	Capital	100 million yen
6	Shareholders	CMIC Holdings 49.9%, Dai Nippon Printing 50.1%

Future expansion
- Our challenge towards maximizing personal health value -

CMIC Group CEO
Dr. Kazuo Nakamura

Healthcare Revolution – CMIC's Philosophy

Concept proposed in 2005

PHVC

Personal Health Value Creator

A group of professionals who can contribute to a new era of health care (person-centered health care)

Personal Health Value

Developed in 2015

CMIC'S CREED

Our CREED

CMIC Group will bring innovation to healthcare
so that all people, regardless of age, gender or race,
can live their one and only lives according to their own will.

Whether in youth, when potential has yet to blossom, or in later years,
when the fruits of one's life are maturing, every individual
has an equally earnest desire to live every moment to its fullest.
We wish to genuinely answer each and every one of these wills to live.

To achieve this, we aspire to always challenge ourselves for a better future.
By evolving and gaining new perspectives,
we will create value out of our unwavering determination,
and continue to contribute to society and humanity.

PHVC = Health care services based on individual health values

Not existing concepts such as treatment based on conventional medicine, disease prevention, and MIBYO (presymptomatic medicine)

Towards the realization of personalized healthcare

To let everyone live their once and only life to its fullest, it is important not only to devote our efforts in disease treatment, but also to hold the perspective of IKIGAI: Happiness of each and every person. Such spirit is embodied in CMIC's CREED, which is at the core of our innovation to bring about new healthcare value.

CMIC

Healthcare Revolution

Healthcare Revolution

Aiming to create businesses that contribute to the maintenance and promotion of personal health and to create a new platform

Healthcare Revolution2.0 (from 2021)

- Response to the changing environment due to COVID-19
- Providing individuals and municipalities with new ecosystem solutions

Healthcare Revolution1.0 (from 2019)

- Realization of CMIC CREED
- Establishment of In-House Healthcare Professional System and Talent Development
- Transformation from Pharma Model to Innovative Healthcare Pharma Model

Healthcare Revolution 2.0

Response to the changing environment due to COVID-19

- Demonstrating the Value of Healthcare Talents in Support of Municipalities -

The COVID Vaccine Changed the Value Chain/Supply Chain



CMIC's New Role in the COVID-era

Mass vaccination venue

Vaccine bus

Vaccination made possible on “Vaccine buses” in Tokyo, Japan

Vaccination completed on 45 users and staffs within 1 hour

PCR caravan

Vaccination caravan for medical institutions

【harmo utilization】

1 Check vaccination intervals/vaccine types

2 Secure data management system that separates personal info from vaccination info (Patent#: 6202152)

3 Follow up on those vaccinated based on accurate information

Local government support based on "IKIGAI"

Comprehensive support for infection control and personal health control

Providing healthcare services based on individual health value

- Frailty measures
- Digital Health Support
- Regional healthcare promotion
- Medical MaaS
- Epidemiological Study
- Call Center
- Personal Health Check
- Specific health guidance intervention
- Antigen/PCR Test
- Vaccination
- harmo Service
- Test Kits Sales

We provides our service to

45

Local governments

We also provide a variety of other services to meet needs.

Healthcare Revolution

Aiming to create businesses that contribute to the maintenance and promotion of personal health and to create a new platform

From April 2023

Healthcare Revolution 3.0

Toward the realization of PHVC

From 2021

Healthcare Revolution 2.0

From 2019

Healthcare Revolution 1.0

PHVC: Personal Healthcare Value Creator

Healthcare Revolution 3.0

towards the realization as Personal Healthcare Value Creators

“nanacara”, a platform for intractable and rare diseases

nanacara

Seizure Recording App Born from the Voices of Patient Families and Epileptologists

Smartphone app that allows children with epilepsy and their families to manage and share daily information such as medication status and seizure frequency with family members and doctors



Main Features

- Seizure recording and management functions
- Medication history management
- Ability to connect with Dr.

Aiming to provide a wide range of patient-centered services by expanding services based on nanacara to other therapeutic areas

Operate a platform with high app usage

The monthly usage rate of the app (nanacara) by patients' families is as high as approximately 60%.

nanacara

System to solve the gap between patients and doctors when treating epilepsy
Quickly communicate correct seizure records to physicians and other health care professionals

Patients with epilepsy: 1 million
Patients with intractable epilepsy: 300,000(including 100,000 children)

Pediatric epilepsy use: approx. 25,000

Epileptologists: 700Number of medical institutions: 450

Medical institutions: approx. 200

Enrollment of patients with intractable epilepsy symptoms and many rare diseases
Seizure and medication data can be analyzed and reported



Disease/Symptom Segment
- West syndrome
- Dravet syndrome
- Lennox syndrome
- Rett syndrome
- Tuberous sclerosis complex
- Ohtahara syndrome
- CDKL5 deficiency disorder
- Aicardi syndrome
- MECP2 duplication syndrome
- Angelman syndrome
- Fukuyama congenital muscular dystrophy

etc.

Examples of Recorded Data
- Medications
- Prescription trends
- Seizure frequency
- Number of seizures
- Seizure onset time
- Seizure duration

- Age
- Gender
- Place of residence
- Family medical institution
- Family doctor

"nana-medi", an online medical service specializing in epilepsy care

nana-medi

Online medical consultation and pharmacy app

Able to connect with a doctor or pharmacist from home or work via a smartphone and receive medical consultation and medication guidance.

It is estimated that there are approximately 1 million epilepsy patients in Japan, but specialists are concentrated in urban areas and there is a large regional bias. The use of digital devices is expected to improve regional disparities in epilepsy treatment.

Our app is the de facto standard for pediatric epilepsy treatment apps

Apps distributed to medical institutions mainly through referrals from patients' families. Used by about half of Epileptologists.

【region around Osaka, Kyoto, Nara)】
- 大阪市立総合医療センター（大阪）
- 大阪母子医療センター（大阪）
- 大阪大学医学部附属病院（大阪）
- 大阪公立大学医学部附属病院（大阪）
- 市立ひらかた病院（大阪）
- 小出内科神経科（大阪）
- 市立吹田市民病院（大阪）
- 八尾市立病院（大阪）
- 近畿大学病院（大阪）
- 京都大学医学部附属病院（京都）
- 京都第二赤十字病院（京都）
- 市立福知山市民病院（京都）
- おおまえハローキッズクリニック（京都）
- 天理よろづ相談所病院（奈良）
- 奈良県総合医療センター（奈良）
- 滋賀医科大学附属病院（滋賀）
- 済生会守山市民病院（滋賀）
- 長浜赤十字病院（滋賀）
- くまだキッズ・ファミリークリニック（滋賀）
- 滋賀県立小児保健医療センター（滋賀）
- 鈴鹿回生病院（三重）
- 神戸市総合療育センター（兵庫）
- 神戸大学医学部附属病院（兵庫）
- 兵庫県立尼崎総合医療センター（兵庫）
- 市立伊丹病院（兵庫）
- 兵庫県立こども病院（兵庫）
- 加古川中央市民病院（兵庫）
- 北播磨総合医療センター（兵庫）
- あだちこども診療所（兵庫）
- えがおのはなこどもクリニックおやざと小児科（兵庫）
- 奈良県立医科大学附属病院（奈良）　他

【Chugoku, Shikoku, Kyushu, Okinawa】
- 琉球大学病院（沖縄）
- 沖縄県立南部医療センター・こども医療センター（沖縄）
- 鹿児島大学病院（鹿児島）
- 鹿児島市立病院（鹿児島）
- 大分大学医学部附属病院（大分）
- 大分県立病院（大分）
- 宮崎大学医学部附属病院（宮崎）

- くまもと江津湖療育医療センター（熊本）
- 佐賀大学医学部附属病院（佐賀）
- 長崎大学病院（長崎）
- 国立病院機構 長崎医療センター（長崎）
- 長崎県立こども医療福祉センター（長崎）
- ひなみこどもクリニック（長崎）
- 佐世保市総合医療センター（長崎）
- 佐世保中央病院（長崎）
- 久留米大学病院（福岡）
- 福岡大学病院（福岡）
- 福岡徳洲会病院（福岡）
- 広島市立舟入市民病院（広島）
- 倉敷中央病院（岡山）
- 川崎医科大学総合医療センター（岡山）
- 鳥取大学医学部付属病院（鳥取）
- 医療法人臼井会 田野病院（高知）　他



201 hospitals

326 doctors

【Tohoku/Hokkaido】
- 北海道立旭川子ども総合療育センター（北海道）
- 札幌医科大学付属病院（北海道）
- NTT東日本札幌病院（北海道）
- マロニエ通クリニック（北海道）
- 秋田県立医療療育センター（秋田）
- 宮城県立こども病院（宮城）　他

【Central Local】
- 岐阜県総合医療センター（岐阜）
- あいち小児保険医療総合センター（愛知）
- 名古屋市立大学病院（愛知）
- すずかけクリニック（愛知）
- 名古屋市立大学病院（愛知）
- 石川県立中央病院（石川）
- 金沢医科大学病院（石川）
- 浅ノ川総合病院（石川）
- 富山大学附属病院（富山）
- 国立病院機構西新潟中央病院（新潟）
- 山梨大学医学部附属病院（山梨）
- 信州大学医学部附属病院（長野）
- 信州上田医療センター（長野）
- 長野県立こども病院（長野）　他

【eastern half of Japan, including Tokyo】
- 国立精神・神経医療研究センター（東京）
- 昭和大学病院（東京）
- 順天堂大学医学部附属病院（東京）
- 日本大学医学部附属板橋病院（東京）
- 東京慈恵会医科大学附属病院（東京）
- 東京西徳洲会病院（東京）
- 東小金井小児神経・脳神経内科クリニック（東京）
- 新宿神経クリニック（東京）
- 東京医科大学病院（東京）
- 杏林大学医学部付属病院（東京）
- 相模台病院（神奈川）
- たくこどもクリニック（神奈川）
- 横須賀市立うわまち病院（神奈川）
- 横浜市立大学附属市民総合医療センター（神奈川）
- 東邦大学医療センター佐倉病院（千葉）
- 東千葉メディカルセンター（千葉）
- 防衛医科大学校病院（埼玉）
- 土浦協同病院（茨城）
- 筑波大学附属病院（茨城）
- 茨城県立こども病院（茨城）
- 西部メディカルセンター（茨城）
- 群馬県立小児医療センター（群馬）
- 群馬大学医学部付属病院（群馬）
- 獨協医科大学病院（栃木）　他

PHR

Personal Health Record

PHR (Personal Health Record)

Personal Health Record

A system in which individuals collect their own medical, health, and nursing care information using digital technology and store it centrally. The data can then be provided to medical institutions and used for other purposes.

Governments, municipalities, and private companies are focusing on the use of PHRs to improve individual health and lifestyle

Electronic Medication Notebook Guidelines Revised Significantly for the First Time in Eight Years

The rules to be followed by e-medicine notebook providers and medical institutions that have introduced the e-medicine notebook, “Operational considerations for the e-medicine notebook," have been overridden as the "Guidelines for the e-medicine notebook," the first major revision in about eight years

ールとして活用されることが期待される。また、他の PHR サービスとの連携等により、体重等の各種健康情報と併せて健康づくりの支援ツールとして活用されること、オンライン服薬指導やオンライン診療のサービスなど関連したサービスと連携することが期待される。現状では紙のお薬手帳の利用者が多いが、今後は、すべての薬局、診療所、病院で電子版お薬手帳サービスの活用を推進することが望まれる。各提供薬局・診療所・病院（以下「提供施設」という。）等において、電子版お薬手帳の意義・役割や活用方法を広く周知するとともに、利用を推奨することが求められる。

▶ **It clearly states that “all pharmacies, clinics, and hospitals should promote the use of the electronic version of the Medication Record Book service."**

Important points

1. Promotion of electronic rather than paper. Medical institutions were encouraged to use the service
2. Electronic versions of the medicine notebook were clearly positioned as part of PHRs.
3. Secondary use of the e-medicine notebook is now subject to the same standards as PHRs.
4. Functional requirements for the e-medicine notebook were clearly defined.

薬生総発0331第１号
令和５年３月31日

各 ｛都道府県 / 保健所設置市 / 特別区｝ 薬務主管部（局）長 殿

厚生労働省医薬・生活衛生局総務課長
（公印省略）

電子版お薬手帳ガイドラインについて

医薬行政の推進につきましては、平素から格別の御高配を賜り、厚く御礼申し上げます。

電子版お薬手帳については、「お薬手帳（電子版）の運用上の留意事項について」（平成27年11月27日付け薬生総発1127第４号厚生労働省医薬・生活衛生局総務課長通知。以下「留意事項通知」という。）により、利用者にお薬手帳サービスを提供する薬局・医療機関や、アプリケーションの提供やデータ保存を行う運営事業者向けに、運用上の留意事項をお示ししてきたところです。

今般、令和４年度厚生労働省委託事業「データヘルス改革を見据えた次世代型お薬手帳活用推進事業」を通じて、オンライン資格確認の普及、電子処方箋の運用開始、マイナポータルを通じた閲覧範囲の拡大といったデジタル技術の進展を踏まえて電子版お薬手帳に求められる役割・機能、要指導医薬品・一般用医薬品を含めた薬剤情報の一元的な管理の重要性を整理し、先の留意事項通知を踏まえつつ、別添のとおり「電子版お薬手帳ガイドライン」を作成いたしました。本ガイドラインでは、電子版お薬手帳の運営事業者において対応が必要と考えられる事項や、電子版お薬手帳サービスを提供する施設における留意事項をまとめており、本通知の発出に伴い、留意事項通知は廃止いたします。

つきましては、貴管内の薬局、医療機関等の関係団体等に対し、本ガイドラインの周知をいただきますよう、よろしくお願いいたします。

また、本ガイドラインにおいては、「実装すべき機能」、「実装が望ましい機能」、「将来的に実装が望ましい機能」として、電子版お薬手帳に求められる機能を体系的に整理しています。「実装すべき機能」については、本通知の発出から１年を目処として実装いただくよう運営事業者に依頼しておりますので、その旨申し添えます。

Digital Garden City Project Support in Rusutsu Village and Rankoshi Town

Establishing a system that integrates the various information required for infant health checkups and vaccinations using a distribution platform based on blockchain technology, and shares and utilizes it in real time among medical institutions and payers through ID linkage with the My Number system.

Data Distribution infrastructure

オケイオス OKEIOS

- Blockchain technology to ensure information authenticity
- AI technology



app linkage

harmo:

- Real-time Vaccination Record Management
- Technology to separate personal information from data

CMIC's Goals

From CRO to PVC and PHVC

Evolution of CMIC's Business

CRO

Contract Research Organization

A group skilled in drug development

PVC

Pharmaceutical Value Creator

A group of professionals who can contribute to the evolution of the pharmaceutical industry

PHVC

Personal Health Value Creator

A group of professionals who can further develop PVC and contribute to the healthcare needs of individuals

PVC

Pharmaceutical Value Creator

A group of professionals who can contribute to the evolution of the pharmaceutical industry

Thank you for your attention.

Cautionary statement:

This translation is prepared and provided for readers' convenience only. In the event of any discrepancy between this translated document and the original Japanese document, the original document shall prevail.

This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management, and is subject to significant risks and uncertainties. Actual financial results may vary materially from the content of this material depending on a number of factors. While this material contains information on pharmaceuticals (including compounds under development), this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of their preparations, promote any kind of unapproved uses, nor provide medical advice of any kind.